Asher J Schranz1, Aaron Fleischauer2, Vivian H Chu3, Li-Tzy Wu4, David L Rosen1. 1. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (A.J.S., D.L.R.). 2. Centers for Disease Control and Prevention, Atlanta, Georgia (A.F.). 3. Duke University School of Medicine, Durham, North Carolina (V.H.C.). 4. Duke University School of Medicine, Duke University Medical Center, and Duke University, Durham, North Carolina (L.W.).
Abstract
Background: Drug use-associated infective endocarditis (DUA-IE) is increasing as a result of the opioid epidemic. Infective endocarditis may require valve surgery, but surgical treatment of DUA-IE has invoked controversy, and the extent of its use is unknown. Objective: To examine hospitalization trends for DUA-IE, the proportion of hospitalizations with surgery, patient characteristics, length of stay, and charges. Design: 10-year analysis of a statewide hospital discharge database. Setting: North Carolina hospitals, 2007 to 2017. Patients: All patients aged 18 years or older hospitalized for IE. Measurements: Annual trends in all IE admissions and in IE hospitalizations with valve surgery, stratified by patients' drug use status. Characteristics of DUA-IE surgical hospitalizations, including patient demographic characteristics, length of stay, disposition, and charges. Results: Of 22 825 IE hospitalizations, 2602 (11%) were for DUA-IE. Valve surgery was performed in 1655 IE hospitalizations (7%), including 285 (17%) for DUA-IE. Annual DUA-IE hospitalizations increased from 0.92 to 10.95 and DUA-IE hospitalizations with surgery from 0.10 to 1.38 per 100 000 persons. In the final year, 42% of IE valve surgeries were performed in patients with DUA-IE. Compared with other surgical patients with IE, those with DUA-IE were younger (median age, 33 vs. 56 years), were more commonly female (47% vs. 33%) and white (89% vs. 63%), and were primarily insured by Medicaid (38%) or uninsured (35%). Hospital stays for DUA-IE were longer (median, 27 vs. 17 days), with higher median charges ($250 994 vs. $198 764). Charges for 282 DUA-IE hospitalizations exceeded $78 million. Limitation: Reliance on administrative data and billing codes. Conclusion: DUA-IE hospitalizations and valve surgeries increased more than 12-fold, and nearly half of all IE valve surgeries were performed in patients with DUA-IE. The swell of patients with DUA-IE is reshaping the scope, type, and financing of health care resources needed to effectively treat IE. Primary Funding Source: National Institutes of Health.
Background: Drug use-associated infective endocarditis (DUA-IE) is increasing as a result of the opioid epidemic. Infective endocarditis may require valve surgery, but surgical treatment of DUA-IE has invoked controversy, and the extent of its use is unknown. Objective: To examine hospitalization trends for DUA-IE, the proportion of hospitalizations with surgery, patient characteristics, length of stay, and charges. Design: 10-year analysis of a statewide hospital discharge database. Setting: North Carolina hospitals, 2007 to 2017. Patients: All patients aged 18 years or older hospitalized for IE. Measurements: Annual trends in all IE admissions and in IE hospitalizations with valve surgery, stratified by patients' drug use status. Characteristics of DUA-IE surgical hospitalizations, including patient demographic characteristics, length of stay, disposition, and charges. Results: Of 22 825 IE hospitalizations, 2602 (11%) were for DUA-IE. Valve surgery was performed in 1655 IE hospitalizations (7%), including 285 (17%) for DUA-IE. Annual DUA-IE hospitalizations increased from 0.92 to 10.95 and DUA-IE hospitalizations with surgery from 0.10 to 1.38 per 100 000 persons. In the final year, 42% of IE valve surgeries were performed in patients with DUA-IE. Compared with other surgical patients with IE, those with DUA-IE were younger (median age, 33 vs. 56 years), were more commonly female (47% vs. 33%) and white (89% vs. 63%), and were primarily insured by Medicaid (38%) or uninsured (35%). Hospital stays for DUA-IE were longer (median, 27 vs. 17 days), with higher median charges ($250 994 vs. $198 764). Charges for 282 DUA-IE hospitalizations exceeded $78 million. Limitation: Reliance on administrative data and billing codes. Conclusion:DUA-IE hospitalizations and valve surgeries increased more than 12-fold, and nearly half of all IE valve surgeries were performed in patients with DUA-IE. The swell of patients with DUA-IE is reshaping the scope, type, and financing of health care resources needed to effectively treat IE. Primary Funding Source: National Institutes of Health.
Authors: Elana S Rosenthal; Adolf W Karchmer; Jesse Theisen-Toupal; Roger Araujo Castillo; Chris F Rowley Journal: Am J Med Date: 2015-11-18 Impact factor: 4.965
Authors: Helen T D'Couto; Gregory K Robbins; Kevin L Ard; Sarah E Wakeman; Justin Alves; Sandra B Nelson Journal: Open Forum Infect Dis Date: 2018-04-18 Impact factor: 3.835
Authors: Makoto Mori; Syed Usman Bin Mahmood; Asher J Schranz; Ibrahim Sultan; Andrea L Axtell; Nadeen Sarsour; William Hiesinger; Marko T Boskovski; Sameer Hirji; Tsuyoshi Kaneko; Joseph Woo; Paul Tang; Arminder S Jassar; Pavan Atluri; Bryan A Whitson; Thomas Gleason; Arnar Geirsson Journal: J Thorac Cardiovasc Surg Date: 2019-07-10 Impact factor: 5.209
Authors: Arnar Geirsson; Asher Schranz; Oliver Jawitz; Makoto Mori; Liqi Feng; Brittany A Zwischenberger; Alexander Iribarne; Joseph Dearani; Gregory Rushing; Vinay Badhwar; Juan A Crestanello Journal: Ann Thorac Surg Date: 2020-05-06 Impact factor: 4.330
Authors: Alysse G Wurcel; Griffin Boll; Deirdre Burke; Rani Khetarpal; Patrick J Warner; Alice M Tang; Kenneth G Warner Journal: Ann Thorac Surg Date: 2019-10-17 Impact factor: 4.330